Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. is listed today as Lyell Immunopharma, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2020 | $493 M | No. 1 | $250 million to $1 billion | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Lyell Immunopharma, Inc., its revenue in fiscal 2025 came from these business segments: Reportable segment $40,000 (100%).
Annual report (SEC XBRL) · Dec 2025
Lyell Immunopharma, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).
SEC Form D · Mar 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2020
Products and services#
No products or services of Lyell Immunopharma, Inc. are on record.
Investors#
7 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | Venture capital | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Fund IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners IX, LLC | Venture capital | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners IX, L.P. | Venture capital | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| ARCH Venture Partners IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A and C preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| GSK PLC | Fund or asset manager | not stated | not stated | Held Series AA preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Hans Edgar Bishop | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 10 investors.
Largest shareholders today
Institutions holding Lyell Immunopharma, Inc. shares, as of Sep 30, 2026.
- ARCH Venture Management, LLC$32 M13.21%
- GSK plc$15 M6.15%
- BlackRock, Inc.$8 M3.25%
- Orland Properties Ltd$7 M3.07%
- Vanguard Capital Management LLC$7 M3.05%
- Almitas Capital LLC$4 M1.82%
- AQR Capital Management LLC$3 M1.41%
- venBio Partners LLC$3 M1.37%
- Alphabet Inc.$3 M1.19%
- Opaleye Management Inc.$3 M1.19%
- Geode Capital Management, LLC$3 M1.12%
- State Street Corp$2 M0.78%
- Renaissance Technologies LLC$2 M0.77%
- Two Sigma Investments, LP$2 M0.68%
- HSG Holding Ltd$1 M0.62%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Elizabeth Homans | Executive officer | Mar 2020 |
| Heather Turner | Executive officer | Mar 2020 |
| Margo Roberts | Executive officer | Mar 2020 |
| Nicholas Restifo | Executive officer | Mar 2020 |
| Richard Goold | Executive officer | Mar 2020 |
| Richard Klausner | Executive officer | Mar 2020 |
| Stan Riddell | Executive officer | Mar 2020 |
| Stephen Hill | Executive officer | Mar 2020 |
| Catherine Friedman | Director | Mar 2020 |
| Hans Bishop | Director | Mar 2020 |
| Richard Klausner | Director | Mar 2020 |
| Robert Nelson | Director | Mar 2020 |
| Richard Klausner | Promoter | Mar 2020 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.